Germany, Berlin Prof. Jalid Sehouli is a Moroccan-German gynaecologist and oncologist specializing in peritoneal and ovarian cancer, and one of Europe’s most distinguished leaders in gynecologic oncology. He currently serves as President of the European Society of Gynecological Oncology (ESGO), Director of the Department of Gynecology with Center for Oncological Surgery at Charité – Universitätsmedizin Berlin, Head of the Charité Gynecological Cancer Center and European Competence Center for Ovarian Cancer, and Deputy Director of the Charité Comprehensive Cancer Center. A full W3 Professor for Life at Charité, he is the author of several hundred scientific publications, the lead of numerous national and international clinical trials, and a committed advocate for patient-centered communication, diversity in clinical research, and cancer survivorship. Beyond his scientific work, Prof. Sehouli is also an acclaimed author of both scientific and literary works, and a recipient of multiple international honors including the Cultures of Peace Award and Morocco’s Order of Merit.
Current Positions
- President, European Society of Gynecological Oncology (ESGO)
- Director, Department of Gynecology with Center for Oncological Surgery, Charité – Universitätsmedizin Berlin, Germany
- Head, Charité Gynecological Cancer Center and European Competence Center for Ovarian Cancer, Charité – Universitätsmedizin Berlin
- Deputy Director, Charité Comprehensive Cancer Center, Berlin, Germany
- Full W3 Professor of Gynaecology (for life), Charité – Universitätsmedizin Berlin (since 2014)
- Spokesman, Organ Commission Ovar, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)
- Board Member, Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO e.V.) (since 1998)
Education
- Medical Studies, Freie Universität Berlin, 1989–1995
- Doctorate, Humboldt-Universität zu Berlin, 1998 — thesis: “Post-operative Use of Unconventional Cancer Therapies in Gynaecological Oncology”
- Specialist Certification, Gynaecology and Obstetrics, 2002
- Habilitation, Humboldt-Universität zu Berlin, 2005 — postdoctoral thesis: “Multimodal Management of Malignant Ovarian Tumours”
Professional Experience
- Appointed to teach Gynaecology and Obstetrics, 2005
- W2 Professor, Charité – Universitätsmedizin Berlin, 2007
- W3 Full Professor for Gynaecology (for life) and Director, Clinic for Gynaecology, Charité – Universitätsmedizin Berlin, 2014–present
- Chairman, Gesellschaft für Geburtshilfe und Gynäkologie in Berlin, 2015–2016
- Deputy Director, Charité Comprehensive Cancer Center, Berlin, present
- Lead and investigator, numerous national and international Phase I, II, and III clinical trials in targeted therapies for gynecologic cancers
- Co-editor of various professional journals and author/co-author of several hundred peer-reviewed articles
Research Activity
- Ovarian and peritoneal cancer: Internationally recognized for leadership in surgical and systemic management of advanced ovarian cancer, including cytoreductive surgery, PARP inhibitor maintenance strategies, HRD biomarker testing, and de-escalation chemotherapy approaches (ENGOT-ov62 / N-PLUS study)
- PARP inhibitors and precision medicine: Principal and co-investigator in key clinical trials including ENGOT-ov48/EUDARIO, PAOLA-1, C-PATROL, GANNET53, and INNOVATE-3; contributor to ESGO-ESMO-ESP consensus guidelines on ovarian cancer
- Endometrial cancer: Lead investigator and contributor in the SIENDO/ENGOT-EN5, DUO-E, ENGOT-EN20/XPORT-EC-042, and PALEO trials; contributor to 2023 FIGO staging discussions and molecular subgroup analyses
- Survivorship and quality of life: Founder and lead of the NOGGO survivorship clinic initiative for long-term gynecological cancer survivors; principal investigator of the EXPRESSION and HANNA survey series; active contributor to circadian rhythm and PARP inhibitor toxicity research (MAMOC trial)
- Diversity and inclusion in clinical trials: Leads GCIG and ENGOT initiatives on inclusion, diversity, equity, and access in gynecologic cancer trials; co-author of the GCIG Barcelona Meeting statements
- Doctor-patient communication: Internationally recognized expert in breaking bad news; author of the book The Art of Breaking Bad News Well (Routledge); leads NOGGO surveys on informed consent and communication practices
- Prehabilitation and perioperative care: Principal investigator of the KORE-INNOVATION trial on prehabilitation and ERAS in ovarian cancer surgery
- NOGGO: Founding board member and scientific leader of NOGGO since 1998; leads the SCOUT-1 non-interventional registry for advanced ovarian cancer management in Germany
- Research in fertility preservation, endometriosis, opportunistic salpingectomy, and rare gynecological tumors
Honors and Awards
- Cultures of Peace Award, International Network City for the Cultures of Peace, Paris, December 2019
- Order of Merit, King Mohammed VI of Morocco, for scientific achievements, 2016
- Roma Focus Award for contributions to gynaecological oncology, 2015
- Diwan Award, Germany, 2017
Memberships / Affiliations
- President, European Society of Gynecological Oncology (ESGO)
- Board Member, Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO e.V.), since 1998
- Spokesman, Organ Commission Ovar, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)
- Gynecological Cancer InterGroup (GCIG) — active member and contributor
- European Network for Gynecological Oncological Trial groups (ENGOT) — active investigator
- EURACAN (European Reference Network for Rare Adult Cancers) — contributor
- Co-editor of multiple professional oncology journals
- Member, various national and international associations and expert bodies in gynecologic oncology
Areas of Specialization
- Ovarian and peritoneal cancer — surgical and systemic management
- Endometrial cancer
- Rare gynecological tumors and cervical cancer
- Cytoreductive and oncological surgery
- PARP inhibitors and targeted therapies
- Homologous recombination deficiency (HRD) biomarkers
- Clinical trial design and leadership in gynecologic oncology
- Cancer survivorship and quality of life
- Doctor-patient communication and breaking bad news
- Diversity and inclusion in clinical research
- Prehabilitation and perioperative care in gynecologic oncology
- Fertility preservation in gynecological cancer
Publications
Prof. Sehouli has authored and co-authored more than 1,700 publications, including peer-reviewed original articles, clinical trial reports, consensus guidelines, book chapters, and books in both scientific and literary genres.
Select Recent Publications:
Kordowitski P, Lange B, Elias KM, Sehouli J, et al. “Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer.” CA: A Cancer Journal for Clinicians, April 2025.
Sehouli J, Van Gorp T, Braicu EI, González-Martín A, et al. “NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate in patients with platinum-resistant high grade serous ovarian carcinoma.” International Journal of Gynecological Cancer, February 2026.
Sehouli J, Chinczewski L, Sukhina O, Leyronnas C, et al. “What burdens patients with endometrial cancer most: results of the international EXPRESSION XI/IMPROVE survey with 2,761 patients.” International Journal of Gynecological Cancer, February 2026.
Sehouli J, Braicu EI, Armbrust R, Wimberger P, et al. “Surgical care of patients with primary advanced ovarian cancer – results from the 3rd interim analysis of the prospective, non-interventional SCOUT-1 study.” International Journal of Gynecological Cancer, February 2026.
Sehouli J, Roser E, Armbrust R, Braicu EI, et al. “ENGOT-ov62 – reducing chemotherapy duration in high-grade advanced ovarian cancer: A comparison of 3 vs. 6 cycles of platinum-based chemotherapy followed by niraparib maintenance in HRD-positive patients.” International Journal of Gynecological Cancer, February 2026.
Sehouli J, Oza A, O’Donnell J, Bookman M, et al. “Increasing diversity in gynaecological cancer trials: The GCIG statement from the Barcelona Meeting.” International Journal of Gynecological Cancer, February 2025.
Monk BJ, Lorusso D, Fujiwara K, Sehouli J. “Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review.” Cancer Treatment Reviews, April 2025.
Concin N, Braicu EI, Combe P, Vergote I, Sehouli J, et al. “GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer.” Clinical Cancer Research, May 2025.
Lorusso D, Xiang Y, Hasegawa K, Duska LR, Sehouli J, et al. “Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results.” The Lancet, September 2024.
Harter P, Wimberger P, Okamoto A, Aghajanian C, Sehouli J, et al. “Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance in newly diagnosed advanced ovarian cancer without tumor BRCA mutation: Updated results from DUO-O/ENGOT-OV46.” Gynecologic Oncology, November 2024.
Sehouli J, Boer J, Brand A, Bookman MA, et al. “How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.” International Journal of Gynecological Cancer, November 2024.
Vergote I, Copeland LJ, Van Gorp T, O’Malley DM, Sehouli J, et al. “Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.” European Journal of Cancer, February 2025.
Sehouli J, Vergote I, Hamilton EP, Makker V, et al. “Post-hoc analysis evaluating selinexor maintenance therapy in patients with TP53 wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.” Journal of Clinical Oncology, June 2025.
Ledermannl JA, Matias-Guiu X, Amant F, Fagotti A, Sehouli J, et al. “ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.” Annals of Oncology, February 2024.
Select Books:
- The Art of Breaking Bad News Well. Routledge; ISBN 978-0367356682.
- Über die Kunst schlechte Nachrichten gut zu überbringen. Kösel Verlag; ISBN 9783466347025.
- Mit Schreiben zu neuer Lebenskraft. Kösel Verlag; ISBN 9783466347254.Marrakesch. Hamburg, 2012; new edition: Berlin, 2018.
- Und von Tanger fahren die Boote nach irgendwo. Berlin, 2016.
- Handbuch Klinische Studien, 3rd edition. Hamburg, 2014.
All information is sourced from publicly available materials.